Lupin Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Lupin s Ankleshwar Facility Receives EIR from U.S. FDA".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin has received an Establishment Inspection Report (EIR) from the US FDA for its Ankleshwar facility in Gujarat, India. This follows a Pre-Approval Inspection conducted from March 2 to March 7, 2026. An EIR indicates the FDA has completed its review and the facility is in compliance with regulatory standards. Managing Director Nilesh Gupta stated this outcome reflects the company's focus on quality excellence and regulatory compliance. The Ankleshwar facility is one of Lupin's 15 manufacturing sites globally and can now proceed with supplying products to the US market.
This is a positive development for shareholders as it removes regulatory uncertainty around one of Lupin's key manufacturing facilities. The clearance signals that the facility can continue and potentially expand its US operations, which is important for a company deriving significant revenue from the American market.